CO-1686 | CancerGRACE

Utility menu

User account menu

Main menu mobile

FIGHT
EDUCATE
PARTICIPATE
- Online Community
  Go to Online Community Page
- Get Involved
  - Memorials and Tributes
  - Volunteer Opportunities
  Go to Get Involved Page
ABOUT GRACE
SUPPORT GRACE
- Why Give to GRACE
  Go to Why Give to GRACE Page

User menu mobile

Utility menu mobile

Main navigation

FIGHT
EDUCATE
PARTICIPATE
- Online Community
  Go to Online Community Page
- Get Involved
  - Memorials and Tributes
  - Volunteer Opportunities
  Go to Get Involved Page
ABOUT GRACE
SUPPORT GRACE
- Why Give to GRACE
  Go to Why Give to GRACE Page

Header CTAs

Donate

Join Our Next Webinar

Join us for the next live, interactive GRACE webinar featuring current treatment strategies and advancements in Blood Cancers.

Learn More and Register

Breadcrumb

Home
Tagging
CO-1686

CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

Article

Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.

[powerpress]

Read more about CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

Pagination

Previous page
Page 2

Subscribe to CO-1686

Stay up to date on the latest news, community discussions, and updates

Sign up here to receive our free, monthly newsletter. Receive highlights of the newest and most up-to-date posts, events, videos, and articles, and stay in touch!

Main menu footer

FIGHT
EDUCATE
PARTICIPATE
- Online Community
- Get Involved
ABOUT GRACE
SUPPORT GRACE
- Why Give to GRACE

Legal menu

Image

Welcome!

Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.

Take the Tour